In pooled analyses, anti-PD-1 antibodies achieved inspiring improvement on survival (HR, 0.69; 95%CI, 0.59 to 0.80) in patients with advanced NSCLC when compared with docetaxel (Fig. 3). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.